EPISODE · Apr 29, 2026 · 1 MIN
Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
from TheBrief.Health · host TheBrief.Health
At AAN Annual Meeting 2026, ADAPT Jr showed efgartigimod alfa delivered durable adolescent gMG improvements, with 80% achieving minimal symptom expression by cycle two and consistent responses.
What this episode covers
At AAN Annual Meeting 2026, ADAPT Jr showed efgartigimod alfa delivered durable adolescent gMG improvements, with 80% achieving minimal symptom expression by cycle two and consistent responses.
NOW PLAYING
Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m